Executive Profiles

Rick Krohn talks to Pharm Exec about the pharma applications of one of tech’s hottest solutions – blockchain.

In this Q&A, American-born David Meek, today CEO of Paris-based multinational Ipsen, discusses the drugmaker's bold global expansion and R&D transformation-driven by revamped leadership, a biotech mindset, and promoting external innovation.

Leaders at Novartis share how the big pharma is laying the foundations for a potential new operating model as a "medicines and data science company."

As part of its digital transformation, last year Novartis recruited Raj Patil, as Head of Data Strategy, and Shahram Ebadollahi as Head of Data Science and Advanced Analytics. Here they talk to Pharm Exec about the task that lies ahead.

How patient support programs have changed over the past two decades, considering adding safety data collection to the mix, and what regulations are driving pharma to adopt pharmacovigilance.

Andre Heeg, Sandor's new Head of Digital, tells Pharm Exec about his digital vision for the company.

Hilary Hutton-Squire, Gilead’s UK & Ireland General Manager, talks to Pharm Exec about the company's new "HIV Age Positively" campaign.

Pharm Exec speaks to Mark Lambrecht, Director of the Health and Life Sciences Global Practice at SAS, about the growing role of big data analytics in pharma and how the industry is evolving to keep pace with it.

Michael Wong talks to Pharm Exec about the takeaways from November's Harvard Business School Healthcare Alumni Association conference on how AI can successfully deliver value for pharma companies.

Ablexis licenses the AlivaMab Mouse, a transgenic mouse that “dramatically improves upon other antibody discovery platforms”. CEO Larry Green tells PharmExec about the evolution of the company and the main challenges associated with the pre-clinical discovery of monoclonal antibodies.

Anjum Swaroop, Vice President and Head of IP at Dr. Reddy's, talks to Pharm Exec about her journey with the company and about what the future holds for this major US generics player.

As this year's ESMO gets under way, Pharm Exec spoke to James Campbell-global franchise business head at Merck KGaA, Darmstadt, Germany-to discuss his vision for the company as a global leader in oncology.

Pharm Exec speaks to Inovio Pharmaceutical's Dr. J. Joseph Kim about his journey from humble beginnings as an 11-year-old Korean immigrant to his present position at the forefront of a new medical frontier.

Pharm Exec talks with CSL Limited’s top executive about the realities of running the global, Australian-headquartered specialty biotech company and sustaining a strong focus in a fast-encroaching era of disruptive technologies and new priorities in innovation and R&D.

Tommy Bramley and Kristine Flemister discuss today’s increasingly complex healthcare environment, and share insights into how stakeholders should be evolving to better help patients and providers navigate barriers around access and affordability.

DIA’s global chief executive talks with Pharm Exec about the current trajectory of patient-centric product development and the need to establish common pathways and metrics to best harness its benefits in everyday practice.

Though challenges in space and affordability remain, New York City is emerging as a hotspot for biotech incubators, including one unique startup based in the city’s fast-growing innovation center, whose CEO, like many C-suite veterans, made the career leap from the big pharma world to forging new discoveries in medical science.

Roche's Marcus Gerund is working to bring healthcare to some of the poorest areas of the world.

While the field of regenerative medicine has grown considerably since the ’90s-in innovation and acceptance-entrenched companies such as Athersys are looking to forge new advances in the stem cell arena by transforming promising science into real-world treatments.

Raman Sehgal talks to three industry leaders for their insights on the challenges faced across the life science sector and how the EMA needs to respond.

At this month's AMPLEXOR Life Sciences’ “Be The Expert” conference, Pharm Exec caught up with Steve Gens, who talked about the evolution of Regulatory Information Management (RIM) and offered some predictions for 2022.

Ilyssa Levins talks to Pharm Exec about some of the regulatory, compliance and legal challenges posed by the digital health revolution.

Rani Therapeutics CEO Mir Imran recounts the lessons he's learned in founding more than 20 life sciences companies and developing more than 400 patents.

Dr. Ann Aerts, head of the Novartis Foundation, Switzerland talks with Pharm Exec about the Novartis Foundation initiatives.

A former biology major, biotech investment banker, and venture capitalist, Tim Sullivan brings that sought-after melding of business and scientific perspectives to his role as chief financial officer for Apellis, a clinical-stage drug company hopeful of ushering in novel protein inhibitors form autoimmune disease.